Does metformin affect kidneys
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
The Impact of Metformin on Kidney Function
Introduction to Metformin and Kidney Health
Metformin is a widely used medication for managing type 2 diabetes mellitus (T2DM). Beyond its glucose-lowering effects, recent research has explored its potential impact on kidney health, particularly in conditions such as acute kidney injury (AKI), chronic kidney disease (CKD), and diabetic kidney disease (DKD).
Metformin and Acute Kidney Injury (AKI)
Several studies have investigated the effects of metformin on AKI. Metformin has been shown to protect renal tubular cells from inflammation, apoptosis, and oxidative stress through the activation of AMP-activated protein kinase (AMPK). This protective effect has been observed in various animal models of AKI, suggesting that metformin could be beneficial in preventing or mitigating kidney damage in acute settings.
Metformin and Chronic Kidney Disease (CKD)
Metformin's role in CKD has been extensively studied. Clinical and preclinical data indicate that metformin can exert renoprotective effects by reducing inflammation, oxidative stress, and fibrosis in the kidneys . In patients with CKD, metformin use has been associated with reduced all-cause mortality and cardiovascular events, particularly in those with mild to moderate CKD (stages G1-3). However, caution is advised when prescribing metformin to patients with advanced CKD due to the risk of lactic acidosis.
Metformin in Diabetic Kidney Disease (DKD)
In the context of DKD, metformin has demonstrated significant benefits. Experimental studies have shown that metformin can attenuate DKD by suppressing renal inflammation, oxidative stress, and fibrosis. Clinical studies support these findings, showing that metformin use is associated with reduced progression to end-stage renal disease (ESRD) and lower mortality rates in T2DM patients with CKD.
Metformin and Polycystic Kidney Disease (PKD)
Metformin has also been investigated for its effects on autosomal dominant polycystic kidney disease (ADPKD). A phase 2 trial found that metformin was safe and tolerable in ADPKD patients, with a slight reduction in the decline of estimated glomerular filtration rate (eGFR). However, the study concluded that larger trials are needed to confirm the efficacy of metformin in slowing disease progression.
Metformin and Kidney Cancer
Emerging evidence suggests that metformin may reduce the risk of kidney cancer in patients with T2DM. A study using the National Health Insurance database in Taiwan found that metformin use was associated with a significantly lower risk of developing kidney cancer compared to non-users. This protective effect was observed across different durations of metformin use, indicating a potential dose-response relationship.
Safety Considerations
While metformin has shown promise in various kidney conditions, its use must be carefully monitored, especially in patients with advanced CKD. The risk of metformin-associated lactic acidosis (MALA) remains a critical concern, necessitating cautious administration and regular monitoring of kidney function .
Conclusion
Metformin appears to have a multifaceted impact on kidney health, offering protective benefits in conditions such as AKI, CKD, DKD, and potentially reducing the risk of kidney cancer. However, its use in patients with advanced CKD requires careful consideration due to the risk of lactic acidosis. Further research, particularly large-scale randomized controlled trials, is essential to fully elucidate the renoprotective mechanisms of metformin and to establish safe and effective treatment protocols.
Sources and full results
Most relevant research papers on this topic